Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy

The treatment paradigm for metastatic triple-negative breast cancer (mTNBC) is shifting from a "one-size-fits-all" chemotherapy approach toward highly personalized, biomarker-driven strategies.

During the CURE Educated Patient Breast Cancer Summit at the 49th annual Miami Breast Cancer Conference, Dr. Hope S. Rugo, an oncologist from City of Hope, joined patient advocate Jonise S. Louis to discuss the current hurdles and hopeful breakthroughs in treating this aggressive disease.

Addressing Unmet Needs in Frontline Care

Rugo opened the discussion by highlighting the historical limitations of mTNBC treatment. Traditionally, options were restricted to heavy chemotherapy. While next-generation sequencing (NGS) is now standard, finding actionable mutations remains a challenge.

Rugo emphasized several critical areas where the field must improve:

• Optimal Sequencing: With more drugs available, doctors are still determining the best order of treatment. "Do you need to lose your hair through your first treatment, or could you get the same benefit as a second treatment?" Rugo asked, noting that trial designs often compare new drugs to "standard" chemotherapies that may not be the best clinical benchmarks.
• The Blood-Brain Barrier: Preventing and treating brain metastases remains a high priority, as cancer cells often "escape" to the brain while the rest of the body responds to treatment.
• Patient-Centered Dosing: Rugo advocated for evaluating drug dosages more rigorously to ensure patients receive the lowest effective dose with manageable toxicity, rather than pushing for the maximum tolerated dose by default.

The Fluidity of Cancer Subtypes

The panel took a personal turn as Louis shared her journey. Originally diagnosed with hormone receptor-positive (HR+), HER2- breast cancer, Louis thrived on a CDK4/6 inhibitor for four years. However, a liver biopsy following progression revealed a startling shift: her cancer had transformed into triple-negative.

Rugo clarified that while "basal-like" TNBC (starting as triple-negative) is typically very aggressive, cancers that lose their estrogen receptors (ER) over time often behave differently and can remain sensitive to certain treatments. This underscores the vital importance of repeat biopsies. Rugo noted that "sampling errors" or localized changes in the tumor environment can lead to different results, which directly impact the choice of therapy.

New Tools and Emerging Therapies

A major highlight of the discussion was the advancement in testing and drug classes:

1. Polymorphism Testing: Rugo discussed the new FDA labeling for Xeloda (capecitabine). Patients can now be tested for genetic variations (polymorphisms) in the DPD enzyme. This identifies "intermediate metabolizers" who might otherwise suffer life-threatening toxicity from the drug, allowing for safer, adjusted dosing.
2. Antibody-Drug Conjugates (ADCs): Drugs like Trodelvy (sacituzumab govitecan) and newer "Trop-2" ADCs are showing immense promise. These "smart bombs" deliver chemotherapy directly to cancer cells. Rugo is particularly excited about trials combining ADCs with immunotherapy, even in patients who lack traditional immune markers.
3. Bispecific Antibodies: Drawing on her early career experience, Rugo pointed toward new bispecific antibodies that target both immune checkpoints and blood vessel growth (VEGF), potentially "melting away" tumors that were previously resistant.

A Message for the Newly Diagnosed

When asked for advice for those facing a new diagnosis, Louis offered a perspective rooted in empowerment. She urged patients to define their top priorities — whether that is longevity, quality of life, or minimizing specific side effects — and to communicate those clearly to their care team.

"Know what you would like your life to look like," Louis advised. "Your voice matters. ... You're the one on treatment, not the doctor."

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.